SEC Form 4 · accession 0001209191-18-045591
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Aug 2, 2018
Accepted (ET)
Aug 6, 2018 · 6:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 2, 2018 | M | 2,155 | $91.05 | A | 48,817 | D | |
| Common StockF2,F3 | Aug 2, 2018 | S | 700 | $175.06 | D | 48,117 | D | |
| Common StockF3,F4 | Aug 2, 2018 | S | 400 | $175.88 | D | 47,717 | D | |
| Common StockF3,F5 | Aug 2, 2018 | S | 400 | $176.95 | D | 47,317 | D | |
| Common StockF3,F6 | Aug 2, 2018 | S | 355 | $178.49 | D | 46,962 | D | |
| Common StockF7 | Aug 2, 2018 | S | 300 | $179.38 | D | 46,662 | D | |
| Common Stock | Aug 3, 2018 | M | 1,942 | $86.52 | A | 48,604 | D | |
| Common StockF3,F8 | Aug 3, 2018 | S | 1,142 | $174.50 | D | 47,462 | D | |
| Common StockF3,F9 | Aug 3, 2018 | S | 700 | $175.86 | D | 46,762 | D | |
| Common Stock | Aug 3, 2018 | S | 100 | $176.69 | D | 46,662 | D | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) | |
| Common Stock | holding | — | — | — | 12,215 | I | Held in Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F10 | $91.05 | Aug 2, 2018 | M | 2,155 | D | — | Feb 1, 2026 | Common Stock | 2,155 | 12,932 | D |
| Stock Option (Right to Buy)F11 | $86.52 | Aug 3, 2018 | M | 1,942 | D | — | Feb 2, 2027 | Common Stock | 1,942 | 19,416 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.
- F10The option vests in 16 quarterly installments from 2/2/2016.
- F11The option vests in 16 quarterly installments from 2/3/2017.
- F2Open market sales reported on this line occurred at a weighted average price of $175.06 (range $174.47 to $175.43).
- F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $175.88 (range $175.52 to $176.10).
- F5Open market sales reported on this line occurred at a weighted average price of $176.95 (range $176.62 to $177.21).
- F6Open market sales reported on this line occurred at a weighted average price of $178.49 (range $178.09 to $178.77).
- F7Open market sales reported on this line occurred at a weighted average price of $179.38 (range $179.17 to $179.49).
- F8Open market sales reported on this line occurred at a weighted average price of $174.50 (range $174.17 to $175.07).
- F9Open market sales reported on this line occurred at a weighted average price of $175.86 (range $175.57 to $176.30).